IL6R and diabetes mellitus: In fact, in a post-hoc meta-analysis of three randomized controlled trials of the IL-6R inhibitor sarilumab including 1982 patients with rheumatoid arthritis, Genovese and colleagues showed statistically-significant improvements in HbA1c in patients randomized to sarilumab as opposed to placebo (least squares mean difference in HbA1c ranging from −0·21% to −0·69%), which were more pronounced at higher dosages and in patients who also had diabetes [67].